Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028067 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT00028067 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 500 participants.
The verdict
NCT00028067, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the atazanavir and nelfinavir (NFV) treatments in their ability to reduce viral load.
Interventions
- DRUG Atazanavir
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2001-08 |
| Est. Completion | 2002-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028067
The ClinicalTrials.gov registry entry for NCT00028067 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atazanavir is the first listed.
NCT00028067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028067 about?
NCT00028067 is a clinical study titled "A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor". The purpose of this study is to compare the atazanavir and nelfinavir (NFV) treatments in their ability to reduce viral load.
What is the current status of trial NCT00028067?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2001-08. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00028067?
The interventions under investigation include: Atazanavir (DRUG), Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00028067?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.